The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.

Risk warning:

Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.

Today's key assessments and concerns

RBC Capital: Maintaining its "Outperform Market" rating for Compass Pathways ( COMPASS Pathways Plc Sponsored ADR(CMPS.US) ), while raising its price target from $16 to $21.

RBC Capital: Maintaining GH Research's ( GH Research Plc(GHRS.US) ) rating at "Outperforming the Market," while raising the price target from $33 to $40.

HC Wainwright & Co.: Maintaining a "buy" rating on Corcept Therapeutics ( Corcept Therapeutics Incorporated.(CORT.US) ), with a price target raised from $90 to $105.

Roth Capital: Initial rating for IP Strategy ( Heritage Distilling Holding Company, Inc.(IPST.US) ) stock at "Buy", with a target price of $8.2.

HC Wainwright & Co.: Maintaining a "Buy" rating for Plus Therapeutics ( PLUS THERAPEUTICS INC(PSTV.US) ), while lowering the target price from $2 to $1.

The symbol	Classification	Target price	Current price	Percentage of potential increase/decrease	(Classification) Agency
COMPASS Pathways Plc Sponsored ADR(CMPS.US)	to lift	$21.0	$7.17	192.89%	RBC Capital
GH Research Plc(GHRS.US)	to lift	$40.0	$16.73	139.09%	RBC Capital
Corcept Therapeutics Incorporated.(CORT.US)	to lift	$105.0	$43.98	138.74%	HC Wainwright & Co.
Corcept Therapeutics Incorporated.(CORT.US)	to lift	$100.0	$43.98	127.38%	Canaccord Genuity
Definium Therapeutics, Inc.(DFTX.US)	to lift	$36.0	$17.4	106.9%	RBC Capital
Heritage Distilling Holding Company, Inc.(IPST.US)	Initial classification	$8.2	$1.47	457.82%	Roth Capital
PLUS THERAPEUTICS INC(PSTV.US)	cut	$1.0	$0.2711	268.87%	HC Wainwright & Co.
Mobileye Global, Inc. Class A(MBLY.US)	cut	$24.0	$9.8	144.9%	Canaccord Genuity
Trade Desk, Inc. Class A(TTD.US)	cut	$74.0	$36.55	102.46%	Stifel
Phreesia(PHR.US)	cut	$30.0	$15.84	89.39%	DA Davidson

comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)

Lifting

Deutsche Bank upgraded its rating on Applied Materials ( Applied Materials, Inc.(AMAT.US) ) to "buy," raising its price target from $275 to $390.

Morgan Stanley: Maintaining an "underweight" rating on Caterpillar Caterpillar Inc.(CAT.US) ) stock, while raising the price target from $395 to $400.

Stifel: Maintaining Alphabet's ( Alphabet Inc. Class A(GOOGL.US) ) rating at "Buy", while raising the price target from $333 to $346.

Morgan Stanley: Maintaining Intel's Intel Corporation(INTC.US) rating at "market-weighted", while raising the price target from $38 to $41.

Keybanc: Maintaining Intel's ( Intel Corporation(INTC.US) ) rating at "overweight", while raising the target price from $60 to $65.

Evercore ISI Group: Maintaining Intel's ( Intel Corporation(INTC.US) ) rating at "market-matched," while raising the price target from $41.1 to $45.

Stifel: Maintaining a "Hold" rating on Intel ( Intel Corporation(INTC.US) ) stock, while raising the price target from $35 to $42.

Barclays: Maintaining Tesla's ( Tesla Motors, Inc.(TSLA.US) ) rating at "market-weighted", while raising its price target from $350 to $360.

First Coverage

Litchfield Hills: Initial rating for Cycurion ( Cycurion, Inc.(CYCU.US) ) stock at "Buy", with a target price of $7.

Freedom Capital Markets: Initial rating for Hinge Health ( Hinge Health, Inc. Class A(HNGE.US) ) stock at "Buy", with a target price of $59.

B. Riley Securities: Initial rating for N-able ( N-able, Inc.(NABL.US) ) stock at "Buy", with a target price of $10.

Cantor Fitzgerald: Initial rating for Powell Industries ( Powell Industries, Inc.(POWL.US) ) at "neutral", with a price target of $427.

Cantor Fitzgerald: Initial rating for Primoris Services ( Primoris Services Corporation(PRIM.US) ) at "neutral", with a target price of $160.

Freedom Capital Markets: Initial rating for Real Brokerage ( Real Brokerage Inc.(REAX.US) ) at "Buy", with a target price of $4.7.

Cantor Fitzgerald: Initial rating for Sterling Construction ( Sterling Infrastructure, Inc.(STRL.US) ) at "overweight", with a price target of $413.

reduction

Morgan Stanley: Maintaining ARM Holdings PLC Sponsored ADR(ARM.US) Holdings' rating at "overweight", while lowering the price target from $180 to $135.

RBC Capital: Maintains "Independent" rating on Intel Intel Corporation(INTC.US) ) stock, while lowering its price target from $50 to $48.

Citigroup: Maintaining a "neutral" rating on Intel ( Intel Corporation(INTC.US) ) stock, while lowering its price target from $50 to $48.

Stifel: Maintaining a "buy" rating on Meta Platforms Meta Platforms(META.US) ) stock, while lowering the price target from $875 to $785.

Wells Fargo: Maintaining an "overweight" rating on Meta Platforms Meta Platforms(META.US) ) stock, while lowering its price target from $795 to $754.

Morgan Stanley: Maintaining Range Resources Range Resources Corporation(RRC.US) rating at "Market Weight", while lowering the price target from $42 to $40.

Oppenheimer: Maintaining Republic Services ( Republic Services, Inc.(RSG.US) ) rating at "Outperform Market", while lowering the price target from $256 to $255.

UBS: Maintaining a "buy" rating on Microsoft stock ( Microsoft Corporation(MSFT.US) ), while lowering the price target from $650 to $600.

Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.